NTBLQ (Notable Labs) Total Current Liabilities: $2.52 Mil (As of Jun. 2024)


What is Notable Labs Total Current Liabilities?

Notable Labs NTBLQ -90.00% Total Current Liabilities is $2.52 Mil as of Jun. 2024.

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. Notable Labs's total current liabilities for the quarter that ended in Jun. 2024 was $2.52

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Notable Labs Total Current Liabilities Related Terms

Notable Labs Total Current Liabilities Historical Data

* Premium members only.

The historical data trend for Notable Labs's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Notable Labs Total Current Liabilities Chart

Notable Labs Annual Data
Trend Dec21 Dec22 Dec23
Total Current Liabilities
2.34 2.01 2.74

Notable Labs Quarterly Data
Dec21 Dec22 Mar23 Jun23 Dec23 Mar24 Jun24
Total Current Liabilities Get a 7-Day Free Trial 0.00 0.00 2.74 2.51 2.52

Notable Labs Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

Notable Labs's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.904+0.523
+Other Current Liabilities+Current Deferred Liabilities
=0.311+0
=2.74

Notable Labs's Total Current Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Current Liabilities=Accounts Payable & Accrued Expense+Short-Term Debt & Capital Lease Obligation
=1.532+0.546
+Other Current Liabilities+Current Deferred Liabilities
=0.439+0
=2.52

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

What does a Total Current Liabilities of $2.52 Mil mean?
Notable Labs (NTBLQ) has a Total Current Liabilities of $2.52 Mil as of Jun. 2024. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Notable Labs and its competitors.
Is Notable Labs' Total Current Liabilities too high?
Notable Labs' current Total Current Liabilities is $2.52 Mil.
How does Notable Labs' Total Current Liabilities compare to VRTX and REGN?
Notable Labs' Total Current Liabilities of $2.52 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Current Liabilities for a Biotechnology company?
A good Total Current Liabilities depends on the Biotechnology industry context. However, Total Current Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Current Liabilities mean?
A high Total Current Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities with maturity less than one year as recorded on a company's balance sheet. View historical data for Notable Labs and its competitors. Notable Labs's current Total Current Liabilities is $2.52 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Notable Labs stock overvalued right now?
Notable Labs (NTBLQ) has a current Total Current Liabilities of $2.52 Mil. The current Total Current Liabilities is $2.52 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Current Liabilities calculated?
Total Current Liabilities is calculated from a company's financial statements. For Notable Labs (NTBLQ), the current Total Current Liabilities is $2.52 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Notable Labs Business Description

Address 320 Hatch Drive, Foster City, CA, USA, 94404
Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.